Print View Attached Docs:
Alias Names: ABL Mutation Screening / BCR-ABL Sequencing / Imatinib (Gleevec) Resistance / TK Receptor
Methodology: Sequencing
Edit Date: 4/13/2009
Performed: Once weekly
Released: 7-10 days after setup at PeaceHealth Laboratories’ reference lab.
CPT Code: 83891-902B / 83894-902B / 83898-902B x2 / 83909-902B x2 / 83912-902B / 86902-902B
Specimen Collection Details
Collection: Six to seven 4 mL lavender top tube (EDTA) peripheral blood. Draw Monday-Thursday only. Also acceptable: Bone marrow. Note that the lower volume of bone marrow specimen reduces the number of cells and therefore the probability of detecting very low-level leukemia burdens in patients with minimal residual disease. media.
Handling: BLOOD: Stabilize peripheral blood by mixing with RPMI media in equal volumes of blood to media (1:1 ratio). Keep refrigerated. Indicate on the requisition the volume of RPMI tissue culture media used. Specimen MUST be received at PeaceHealth Laboratories’ reference lab within 24 hours of collection.
BONE MARROW: Draw in a heparinized syringe and transfer to an EDTA collection tube. Mix with an equal volume (1:1 ratio) of RPMI. Keep refrigerated.
Stability: Unstable frozen.
Standard Volume: 30 mL whole blood.
Minimum Volume: 20 mL whole blood.
Transport: Refrigerated.
Comments: Direct sequencing of the ABL kinase domain.
Rejection Criteria: Clotted, frozen, or leaking specimen.
This test may require insurance company prior authorization before ordering.
Please check the prior authorization list
Failure to gain preauthorization may result in denial of coverage.

PeaceHealth Laboratories